^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iparomlimab (QL1604)

    i
    Other names: QL1604, PSB103, QL-1604, QL 1604
    Company:
    Qilu Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    16d
    Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Exploring the efficacy and safety of famitinib combined with epalrestat and torivirine in the treatment of advanced and recurrent/metastatic cervical cancer (ChiCTR2500111354)
    P2, N=90, Not yet recruiting, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    famitinib (SHR 1020) • iparomlimab (QL1604)
    1m
    An exploratory study on tuvonralimab/iparomlimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500111278)
    P=N/A, N=20, Not yet recruiting, Cancer Hospital, Chinese academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
    New trial
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A single-arm, multicenter, exploratory clinical study on the third-line treatment of metastatic colorectal cancer with Iparomlimab and Tuvonralimab combined with anti-angiogenic drugs (ChiCTR2500110241)
    P4, N=44, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New P4 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Center, Single-Arm, Phase II Study of QL1706 (Iparomlimab and Tuvonralimab Injection) in Combination with Chemotherapy and Anti-angiogenic Therapy in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Failed Prior Platinum-Based Chemotherapy (ChiCTR2500110068)
    P2, N=30, Not yet recruiting, The Second Affiliated Hospital Zhejiang University School of Medicine; The Second Affiliated Hospital Zhejiang University School of Medicine
    New P2 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Iparomlimab and Tuvonralimab combined with irinotecan liposome is used in recurrent/metastatic nasopharyngeal carcinoma after anti-PD - (L) 1 monoclonal antibody treatment (ChiCTR2500110090)
    P2, N=36, Not yet recruiting, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (ChiCTR2500109864)
    P2, N=42, Not yet recruiting, Qilu Hospital of Shandong University(Qingdao); Qilu Hospital of Shandong University(Qingdao)
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Center, Single-Arm Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined with Platinum-Based Chemotherapy as Neoadjuvant Therapy for Non-Small Cell Lung Cancer (ChiCTR2500109309)
    P=N/A, N=10, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Exploratory clinical study of Iparomlimab and Tuvonralimab (QL1706) in combination with albumin paclitaxel and nedaplatin for locally advanced resectable squamous cell carcinoma of the esophagus (ESCC) (ChiCTR2500109130)
    P=N/A, N=30, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New trial
    |
    albumin-bound paclitaxel • Aqupla (nedaplatin) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Arm, Phase II Exploratory Study of Short-Course Radiotherapy (SCRT) Sequential to Iparomlimab and Tuvonralimab Combined with SOX Chemotherapy for Neoadjuvant Treatment of Gastric/Gastroesophageal Junction Adenocarcinom (ChiCTR2500108226)
    P2, N=38, Not yet recruiting, Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University
    New P2 trial
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Study on the Safety and Efficacy of Iparomlimab and Tuvonralimab Combined with Lenvatinib as Neoadjuvant Therapy for High-Risk Localized and Locally Advanced Renal Cell Carcinoma (ChiCTR2500108135)
    P4, N=19, Not yet recruiting, Shandong Provincial Hospital; Shandong Provincial Hospital
    New P4 trial
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Phase II, Single-Arm, Prospective, Single-Center Study of QL1706 Combined with Trastuzumab, Pertuzumab, and Albumin-Bound Paclitaxel as Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients (ChiCTR2500107837)
    P2, N=76, Not yet recruiting, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)